**5.1. What to do with HIV(+) pregnant women who received previous ART and are currently without ART?**

A CD4 T-cell count, a VL, and a viral genotyping study are recommended in women previously exposed to ART and who discontinued therapy. The latter will enable designing the thera‐ peutic regimen based on patient history and current genotype. Viral load should be assessed after 4 to 6 weeks of the initiation of ART, and a new genotyping study should be performed in case of failure, for adjustment of the latter. Zidovudine should be included in the ART regimen when possible (Grade D recommendation).

Several clinical guidelines propose such management based on expert recommendations (Level 4 evidence) [15-20].
